Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 01 Mar 2023
After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.
Read Full NewsA novel oral ketamine drug shows a signal for reducing depressive symptoms with minimal dissociative effects.
Men who receive personalized estimates of the likelihood of raised prostate-specific antigen levels are more likely to decide to get screening than those who receive general information on pros and cons.
Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis.
Clinicians and patients are already relying on AI, while hospitals are still building the oversight to keep up.
A culturally tailored lifestyle program improves cognition significantly more than standard health advice among older adults at risk for dementia across Latin America.
People with intellectual disabilities who have physical health problems or sensory impairments face a higher risk for challenging behaviours.
Rimegepant is safe and effective in patients with migraine not responding to multiple prior preventive therapies, a real-world study shows.
1.
Similar survival seen with simple versus radical hysterectomy for cervical cancer
2.
New Gene Therapy Nears EU Nod for Bladder Cancer
3.
Breast Cancer Patients Living Longer Post-Medicaid Expansion
4.
Exercise may help breast cancer survivors manage weight
5.
High levels of traumatic stress found in caregivers of adult cancer patients
1.
Senescence in Cancer Therapy: Mechanisms, Clinical Relevance, and Therapeutic Implications
2.
Enhancing Cancer Care: From Diagnosis Through Survivorship and Beyond
3.
The Importance of Understanding Carboxyhemoglobin Levels in the Body: A Comprehensive Guide
4.
Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results
5.
Individualized Hematopoietic Reserve Assessment in Blood Disorders
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part XIII
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
5.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge